Related references
Note: Only part of the references are listed.Japan resumes active recommendations of HPV vaccine after 8·5 years of suspension
Rei Haruyama et al.
LANCET ONCOLOGY (2022)
The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study
Milena Falcaro et al.
LANCET (2021)
Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study
Kate T. Simms et al.
LANCET PUBLIC HEALTH (2020)
Corrected human papillomavirus vaccination rates for each birth fiscal year in Japan
Satoshi Nakagawa et al.
CANCER SCIENCE (2020)
Beyond resumption of the Japanese Government's recommendation of the HPV vaccine
Yutaka Ueda et al.
LANCET ONCOLOGY (2018)
Differential misclassification between self-reported status and official HPV vaccination records in Japan: Implications for evaluating vaccine safety and effectiveness
Manako Yamaguchi et al.
PAPILLOMAVIRUS RESEARCH (2018)
Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine
Suzanne M. Garland et al.
VACCINE (2015)
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine
Sven-Eric Olsson et al.
VACCINE (2007)
Share Paper
